Psomagen, Inc. Logo

Psomagen, Inc.

A contract lab providing multiomics and data analysis solutions for researchers.

950200 | KO

Overview

Corporate Details

ISIN(s):
KR8840150005
LEI:
Country:
United States of America
Address:
City of Wilmington, County of New Castle, State of Delaware, Corporation Trust Cen, Wilmington

Description

Psomagen, Inc. is a contract laboratory service provider specializing in multiomics and data analysis solutions for scientists and clinicians. Operating from CLIA-certified and CAP-accredited facilities, the company offers a comprehensive suite of services to the academic, clinical, and life sciences research communities. Its core offerings encompass genomics, epigenomics, proteomics, transcriptomics, and metagenomics. Psomagen utilizes a range of sequencing technologies, including Sanger sequencing, Next-Generation Sequencing (NGS), and third-generation sequencing. The company also provides specialized solutions such as spatial biology analysis, cell line authentication via STR profiling, and advanced bioinformatics support to analyze complex biological data.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-07-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.4 KB
2021-06-18 00:00
기업설명회(IR)개최
Korean 6.8 KB
2021-05-14 00:00
분기보고서 (2021.03)
Korean 942.6 KB
2021-05-10 00:00
기타경영사항(특허권취득)(자율공시)(마이크로바이옴 분석을 위한 방법과 시스템)
Korean 5.9 KB
2021-03-31 00:00
정기주주총회결과
Korean 19.3 KB
2021-03-23 00:00
감사보고서제출
Korean 20.0 KB
2021-03-23 00:00
사업보고서 (2020.12)
Korean 1.2 MB
2021-03-23 00:00
[기재정정]주주총회소집공고
Korean 157.9 KB
2021-03-16 00:00
주주총회소집공고
Korean 105.6 KB
2021-03-02 00:00
주주총회소집결의
Korean 7.6 KB
2021-03-02 00:00
의결권대리행사권유참고서류
Korean 110.8 KB
2021-03-02 00:00
주주총회집중일개최사유신고
Korean 4.8 KB
2021-02-22 00:00
기타경영사항(특허권취득)(자율공시)(디지털 마이크로 유체 시스템과 방법)
Korean 5.4 KB
2021-02-16 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 12.5 KB
2020-12-16 00:00
기타경영사항(자율공시)(제17기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
Korean 4.6 KB

Automate Your Workflow. Get a real-time feed of all Psomagen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Psomagen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Psomagen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BioSenic SA Logo
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
Belgium
BIOS
BIOTECH Logo
A biotechnology group offering preclinical services, intein development, and licensing.
Spain
BST
Biovica International B Logo
Develops blood-based biomarker assays for cancer therapy monitoring.
Sweden
BIOVIC
Bonus BioGroup Ltd. Logo
A clinical-stage biotech firm developing cell therapy and tissue engineering products.
Israel
BONS
BRAIN Biotech AG Logo
Develops enzymes and microorganisms for the food, chemical, and life sciences sectors.
Germany
BNN
BriaCell Therapeutics Corp. Logo
Clinical-stage immuno-oncology company developing cellular immunotherapies for cancer.
United States of America
BCTX
BSF ENTERPRISE PLC Logo
Develops cell-based solutions for cultivated meat, leather, and corneal repair.
United Kingdom
BSFA
BullFrog AI Holdings, Inc. Logo
A technology company applying AI and machine learning to drug development.
United States of America
BFRG
Burning Rock Biotech Ltd Logo
A global diagnostics company specializing in precision oncology using NGS technology.
United States of America
BNR
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for B cell-mediated autoimmune diseases.
United States of America
CABA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.